Investors in Iot

Pureos Bioventures is a venture capital fund, which invests exclusively in private innovative drug development companies, with a special emphasis on the next generation of biological drugs and drug formats. The fund’s portfolio companies are built on scientific excellence to develop therapies across a broad indication spectrum including oncology, immunology, ophthalmology, rare diseases, and neuroscience. Pureos has built a team with deep investment, operating and clinical expertise, that strives to impact patients’ lives by advancing innovative treatments for devastating diseases.

Provide finance to support the growth of young, innovative businesses in the Leather sector The Leather industry, thanks to the production of leather goods and footwear in particular, has long contributed to France’s reputation around the world, the embodiment of France’s finest products. But it is not only a question of image, powerfully driven by the leading luxury houses; the French leather sector is also an important economic force. It consists of 9 400 companies, generates 25 billion euros of turnover and has nearly 130 000 employees. More than ever, the automation generated by technology, the digital transformation, customization, environmental sustainability, the principle of transparency and the circular economy of models, plus marketing and communication are major agents for change. It is with this in mind, to dynamize the sector and prepare it for tomorrow’s big challenges, that CUIR INVEST wishes to offer financial support to the visionary entrepreneurs that are shaping the future. CUIR INVEST is an investment fund created to offer long-term support to the most promising young innovative businesses in the sector, while respecting the values that drive us.

Metaplanet is an early-stage investment firm making long-term bets on contrarians and leveraging the knowledge and network across sectors. We back mission-driven founders working on positively disruptive deep technologies.

Atmos' mission is to invest in world class founders, who are motivated to solve the world's most challenging issues, through the use of cutting edge technologies and a data driven approach. Atmos backs innovative teams that have cracked complex scientific problems, entrepreneurs who have commercialized their expertise, companies that are indispensable to their clients and management that understands the markets they serve. Atmos partners with teams working to build these enterprises into category leaders.

Elige Capital is an investor specializing in capital transmission and development capital operations for growing SMEs, in minority or majority, for investment tickets between 1 and 4 million euros. A dual DNA: entrepreneurs and investors Elige is led by an independent team that manages two investment vehicles subscribed by private investors who are business leaders and leading institutional investors. A flexible investment strategy whose main criterion is based on the women and men at the head of the companies and their development projects.

PPRS Venture positions itself uniquely in the biotech sector as "The Strategic Partnering Organization," specializing in innovative projects for diagnostics and therapeutics in neuroscience and orphan diseases. Based in Colmar, Alsace, with a subsidiary in Boston, USA, they combine independence in project selection with a multidisciplinary team of 25 associates. This team drives research collaborations encompassing over 100 stakeholders, from CROs to public and private labs. PPRS integrates robust financial and scientific expertise to support projects, from proof of concept to translational medicine, emphasizing risk management and global impact in their strategic approach.

The Fund operates within the BRIdgeAlfa Programme, financing research projects undertaken by young and innovative enterprises. The financing provided by the Fund is of a mixed nature and includes a component of equity financing from the Fund's private investors and a component of grant financing from the National Centre for Research and Development. The Fund’s activities are undertaken in close cooperation with the National Centre for Research and Development, which has its representative on the Fund’s Investment Committee.

We invest in innovation-driven Slovak companies with the potential to become leaders in their segment and succeed on a global scale. INVESTMENT STRATEGY Innovation and teamwork – We like hi-tech industries; however, our focus is not limited to them. Our approach is more comprehensive and what counts the most is the innovation level, the overall uniqueness of the presented solution, and, of course, a skilled team with excellent execution power.

The Normandy Littoral Fund was established to harness the significant natural assets of Normandy's 640 km coastline and its pivotal role in the region's economy, particularly with nearly 50,000 jobs in the seafood sector, making Normandy the second-largest region in France in this domain. Recognizing these strengths and challenges, the fund aims to serve as an active financial partner to maritime stakeholders. Its team, composed of specialists rooted in the region, deeply understands the concerns of maritime professionals and is committed to long-term engagement to support their strategic planning and project implementation. The fund's focus spans the maritime, coastal, and river sectors, aiming to foster sustainable development and growth through strategic investments and tailored financial solutions that contribute to the economic and environmental prosperity of Normandy's maritime economy.

Augere Health Food Fund Sp. z o.o. (augereventure.pl) is a seed fund dedicated to commercializing innovative technologies and products in the food sector, supporting the development of innovative Polish companies promoting health initiatives. We are constantly looking for innovative solutions that we could support in their commercial implementation on the market (

At AdBio Partners, we focus on ground-breaking innovations in Life Sciences to address unmet medical and clinical needs, building the next generation of pioneering healthcare companies. Keeping in mind patients’ well-being, our mission is to improve medical care and advance medical innovations. We collaborate closely with leading research institutions and well-established technology transfer offices, leveraging our strong network of scientific and medical partners to explore new territories, source breakthrough medical discoveries, and drive inventive Life Sciences start-ups to success.

JR HOLDING is an Alternative Joint-Stock Company listed on the NewConnect Exchange Market in Poland since 2012.In accordance with our strategy, we invest in several key sectors of the future, such as renewable sources of energy, gaming, lifestyle, artificial intelligence, new media or biotech. While creating a business, we believe in more than just good projects or sectors of big potential - we believe in people and realtions.